支持内分泌学会成人恶性肿瘤高钙血症治疗临床实践指南的系统综述
本系统综述检索多个数据库,纳入21项研究,评估双膦酸盐、地舒单抗、降钙素等治疗恶性肿瘤高钙血症的获益与危害,采用GRADE方法评价证据质量。多数研究偏倚风险为中等,所有8个临床问题的证据确定性为低至极低。
要点
- 双膦酸盐组高钙血症缓解比例高于安慰剂组,但不良事件发生率显著更高。
- 地舒单抗与双膦酸盐相比,高钙血症缓解率无显著差异。
- 双膦酸盐治疗后使用地舒单抗,三分之二难治/复发性高钙血症患者获得缓解。
核心结论
- 本系统综述总结了恶性肿瘤高钙血症治疗获益与危害的证据,所有8个临床问题的证据确定性为低至极低。
研究设计与样本
- 系统综述,检索多个数据库,纳入21项研究,回答指南小组优先确定的8个临床问题,采用GRADE方法评估证据确定性。
主要发现
- 共审阅1949条引文,最终纳入21项研究,多数纳入研究的偏倚风险为中等。
- 与安慰剂相比,接受双膦酸盐的患者达到高钙血症缓解的比例更高,但双膦酸盐组不良事件发生率显著更高。
- 地舒单抗与双膦酸盐相比,达到高钙血症缓解的患者比例无显著差异。
- 在双膦酸盐治疗后接受地舒单抗的难治/复发性恶性肿瘤高钙血症患者中,三分之二达到高钙血症缓解。
- 在双膦酸盐治疗基础上加用降钙素,未影响高钙血症缓解、血钙正常时间或低钙血症。
关键数值与推荐
- 仅间接证据可用于回答以下问题:与高骨化三醇水平相关的肿瘤高钙血症管理、双膦酸盐使用后难治/复发性恶性肿瘤高钙血症、以及拟钙剂用于甲状旁腺癌相关高钙血症的治疗。
- 所有8个临床问题的证据确定性为低至极低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数纳入研究的偏倚风险为中等。
- 仅间接证据可用于回答与高骨化三醇水平相关的肿瘤高钙血症管理、双膦酸盐使用后难治/复发性恶性肿瘤高钙血症、以及拟钙剂用于甲状旁腺癌相关高钙血症治疗的问题。
- 所有8个临床问题的证据确定性为低至极低。
- 需要关于患者价值观和偏好以及其他重要决策和背景因素的信息,以促进临床推荐的形成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Hypercalcemia is a common complication of malignancy that is associated with high morbidity and mortality. OBJECTIVE: To support development of the Endocrine Society Clinical Practice Guideline for the treatment of hypercalcemia of malignancy in adults. METHODS: We searched multiple databases for studies that addressed 8 clinical questions prioritized by a guideline panel from the Endocrine Society. Quantitative and qualitative synthesis was performed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess certainty of evidence. RESULTS: We reviewed 1949 citations, from which we included 21 studies. The risk of bias for most of the included studies was moderate. A higher proportion of patients who received bisphosphonate achieved resolution of hypercalcemia when compared to placebo. The incidence rate of adverse events was significantly higher in the bisphosphonate group. Comparing denosumab to bisphosphonate, there was no significant difference in the rate of patients who achieved resolution of hypercalcemia. Two-thirds of patients with refractory/recurrent hypercalcemia of malignancy who received denosumab following bisphosphonate therapy achieved resolution of hypercalcemia. Addition of calcitonin to bisphosphonate therapy did not affect the resolution of hypercalcemia, time to normocalcemia, or hypocalcemia. Only indirect evidence was available to address questions on the management of hypercalcemia in tumors associated with high calcitriol levels, refractory/recurrent hypercalcemia of malignancy following the use of bisphosphonates, and the use of calcimimetics in the treatment of hypercalcemia associated with parathyroid carcinoma. The certainty of the evidence to address all 8 clinical questions was low to very low. CONCLUSION: The evidence summarized in this systematic review addresses the benefits and harms of treatments of hypercalcemia of malignancy. Additional information about patients' values and preferences, and other important decisional and contextual factors is needed to facilitate the development of clinical recommendations.
引用
- Seisa MO, Nayfeh T, Hasan B, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults. J Clin Endocrinol Metab. 2023. PMID: 36545700. doi:10.1210/clinem/dgac631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。